552:
666:
674:
662:
681:
37:
329:
325:
375:
333:
321:
30:
697:
496:
412:
277:
247:
639:
567:
534:
341:
379:
101:
702:
643:
527:
212:
506:
470:
442:
371:
125:
520:
196:
315:
253:
201:
81:
299:
169:
147:
116:
91:
74:
651:
450:
287:
208:
291:
178:
86:
50:
15:
257:
8:
164:
96:
581:
417:
367:
182:
111:
69:
647:
491:
455:
422:
347:
269:
46:
265:
186:
140:
135:
571:
460:
283:
238:
486:
407:
359:
152:
64:
691:
465:
432:
427:
546:
307:
191:
501:
355:
228:
218:
609:
will show the template collapsed, i.e. hidden apart from its title bar.
574:), it is hidden apart from its title bar; if not, it is fully visible.
303:
295:
261:
223:
130:
363:
351:
566:, meaning that if there is another collapsible item on the page (a
397:
402:
45:
633:
will show the template expanded, i.e. fully visible.
659:Editors can experiment in this template's sandbox
577:To change this template's initial visibility, the
689:
31:
549:
38:
24:
561:initial visibility currently defaults to
330:Preventable fraction among the unexposed
326:Attributable fraction for the population
334:Preventable fraction for the population
322:Attributable fraction among the exposed
690:
654:for suggestions on style and editing.
19:
572:table with the collapsible attribute
497:Correlation does not imply causation
413:Animal testing on non-human primates
13:
14:
714:
550:
380:Pre- and post-test probability
102:Patient and public involvement
1:
638:This template is part of the
507:Sex as a biological variable
7:
698:Medicine navigational boxes
471:Intention-to-treat analysis
443:Analysis of clinical trials
372:Specificity and sensitivity
126:Randomized controlled trial
10:
719:
658:
682:Subpages of this template
612:
588:
515:
480:Interpretation of results
479:
441:
390:
340:
314:
276:
246:
237:
213:Nested case–control study
163:
110:
57:
617:Medical research studies
593:Medical research studies
82:Academic clinical trials
300:Relative risk reduction
148:Adaptive clinical trial
92:Evidence-based medicine
75:Adaptive clinical trial
555:Template documentation
288:Number needed to treat
292:Number needed to harm
179:Cross-sectional study
131:Scientific experiment
87:Clinical study design
703:Statistics templates
258:Cumulative incidence
165:Observational study
97:Real world evidence
51:experimental design
451:Risk–benefit ratio
418:First-in-man study
368:Case fatality rate
209:Case–control study
183:Longitudinal study
648:Template:Medicine
544:
543:
492:Survivorship bias
456:Systematic review
423:Multicenter trial
386:
385:
376:Likelihood-ratios
348:Clinical endpoint
316:Population impact
270:Period prevalence
47:Clinical research
710:
678:
670:
644:navigation boxes
632:
631:
627:
624:
621:
618:
615:
608:
607:
603:
600:
597:
594:
591:
580:
579:|state=
564:
559:This template's
556:
554:
553:
391:Trial/test types
266:Point prevalence
244:
243:
187:Ecological study
170:EBM II-2 to II-3
141:Open-label trial
136:Blind experiment
112:Controlled study
40:
33:
26:
17:
16:
718:
717:
713:
712:
711:
709:
708:
707:
688:
687:
686:
685:
680:
672:
660:
657:
629:
625:
622:
619:
616:
613:
605:
601:
598:
595:
592:
589:
578:
568:navbox, sidebar
562:
557:
551:
545:
540:
511:
475:
437:
382:
336:
310:
284:Risk difference
272:
233:
167:
159:
114:
106:
70:Trial protocols
53:
44:
12:
11:
5:
716:
706:
705:
700:
671:and testcases
640:Medical series
635:
634:
610:
548:
547:
542:
541:
539:
538:
535:List of topics
531:
524:
516:
513:
512:
510:
509:
504:
499:
494:
489:
487:Selection bias
483:
481:
477:
476:
474:
473:
468:
463:
458:
453:
447:
445:
439:
438:
436:
435:
430:
425:
420:
415:
410:
408:Animal testing
405:
400:
394:
392:
388:
387:
384:
383:
360:Mortality rate
346:
344:
338:
337:
320:
318:
312:
311:
282:
280:
274:
273:
252:
250:
241:
235:
234:
232:
231:
226:
221:
216:
206:
205:
204:
199:
189:
175:
173:
161:
160:
158:
157:
156:
155:
153:Platform trial
145:
144:
143:
138:
133:
122:
120:
108:
107:
105:
104:
99:
94:
89:
84:
79:
78:
77:
72:
65:Clinical trial
61:
59:
55:
54:
43:
42:
35:
28:
20:
9:
6:
4:
3:
2:
715:
704:
701:
699:
696:
695:
693:
683:
676:
668:
664:
656:
655:
653:
649:
645:
641:
611:
587:
586:
585:
584:may be used:
583:
575:
573:
569:
565:
537:
536:
532:
530:
529:
525:
523:
522:
518:
517:
514:
508:
505:
503:
500:
498:
495:
493:
490:
488:
485:
484:
482:
478:
472:
469:
467:
466:Meta-analysis
464:
462:
459:
457:
454:
452:
449:
448:
446:
444:
440:
434:
433:Vaccine trial
431:
429:
428:Seeding trial
426:
424:
421:
419:
416:
414:
411:
409:
406:
404:
401:
399:
396:
395:
393:
389:
381:
377:
373:
369:
365:
361:
357:
353:
349:
345:
343:
339:
335:
331:
327:
323:
319:
317:
313:
309:
305:
301:
297:
293:
289:
285:
281:
279:
275:
271:
267:
263:
259:
255:
251:
249:
245:
242:
240:
236:
230:
227:
225:
222:
220:
217:
214:
210:
207:
203:
200:
198:
197:Retrospective
195:
194:
193:
190:
188:
184:
180:
177:
176:
174:
171:
166:
162:
154:
151:
150:
149:
146:
142:
139:
137:
134:
132:
129:
128:
127:
124:
123:
121:
118:
117:EBM I to II-1
113:
109:
103:
100:
98:
95:
93:
90:
88:
85:
83:
80:
76:
73:
71:
68:
67:
66:
63:
62:
60:
56:
52:
48:
41:
36:
34:
29:
27:
22:
21:
18:
637:
636:
576:
563:autocollapse
560:
558:
533:
526:
519:
308:Hazard ratio
192:Cohort study
23:
646:. Refer to
502:Null result
461:Replication
356:Infectivity
278:Association
229:Case report
219:Case series
202:Prospective
692:Categories
304:Odds ratio
296:Risk ratio
262:Prevalence
248:Occurrence
224:Case study
652:talk page
604:collapsed
582:parameter
364:Morbidity
352:Virulence
254:Incidence
650:and its
628:expanded
528:Glossary
521:Category
398:In vitro
239:Measures
58:Overview
665:|
403:In vivo
679:pages.
675:create
667:mirror
663:create
623:state
599:state
570:, or
342:Other
181:vs.
49:and
642:of
694::
630:}}
614:{{
606:}}
590:{{
378:,
374:,
370:,
366:,
362:,
358:,
354:,
350:,
332:,
328:,
324:,
306:,
302:,
298:,
294:,
290:,
286:,
268:,
264:,
260:,
256:,
185:,
684:.
677:)
673:(
669:)
661:(
626:=
620:|
602:=
596:|
215:)
211:(
172:)
168:(
119:)
115:(
39:e
32:t
25:v
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.